Seizert Capital Partners LLC Cuts Stock Position in Exelixis, Inc. (NASDAQ:EXEL)

Seizert Capital Partners LLC trimmed its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 10.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 419,635 shares of the biotechnology company’s stock after selling 50,305 shares during the quarter. Seizert Capital Partners LLC’s holdings in Exelixis were worth $13,974,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of EXEL. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Exelixis by 18.1% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company’s stock valued at $63,000 after purchasing an additional 290 shares during the period. Steward Partners Investment Advisory LLC grew its stake in shares of Exelixis by 4.9% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company’s stock worth $235,000 after acquiring an additional 330 shares in the last quarter. Covestor Ltd increased its position in shares of Exelixis by 5.7% during the third quarter. Covestor Ltd now owns 6,335 shares of the biotechnology company’s stock worth $164,000 after acquiring an additional 341 shares during the period. Oregon Public Employees Retirement Fund raised its stake in shares of Exelixis by 0.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company’s stock valued at $1,937,000 after acquiring an additional 354 shares in the last quarter. Finally, Principal Securities Inc. boosted its holdings in Exelixis by 62.8% in the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 373 shares during the period. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Trading Down 0.7 %

Shares of EXEL opened at $38.29 on Wednesday. The company’s 50 day simple moving average is $34.72 and its 200-day simple moving average is $31.87. The firm has a market cap of $10.72 billion, a PE ratio of 21.63, a price-to-earnings-growth ratio of 1.13 and a beta of 0.53. Exelixis, Inc. has a 12-month low of $20.14 and a 12-month high of $39.30.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. As a group, equities research analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on EXEL shares. Guggenheim reaffirmed a “buy” rating and issued a $42.00 price target on shares of Exelixis in a research report on Wednesday, February 12th. JMP Securities reaffirmed a “market outperform” rating and issued a $41.00 target price on shares of Exelixis in a report on Thursday, January 23rd. BMO Capital Markets downgraded shares of Exelixis from an “outperform” rating to a “market perform” rating and lifted their price target for the stock from $36.00 to $40.00 in a research note on Friday, December 20th. StockNews.com raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 19th. Finally, Stifel Nicolaus lifted their price objective on shares of Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a research report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $37.24.

Insider Activity at Exelixis

In related news, EVP Patrick J. Haley sold 52,636 shares of the business’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the sale, the executive vice president now owns 303,310 shares of the company’s stock, valued at approximately $11,216,403.80. The trade was a 14.79 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $34.88, for a total transaction of $425,884.80. Following the sale, the director now owns 30,406 shares of the company’s stock, valued at approximately $1,060,561.28. The trade was a 28.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 130,343 shares of company stock worth $4,789,234 in the last quarter. Company insiders own 2.85% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.